

综述

侵袭性真菌感染治疗新进展

李梦, 廖万清

第二军医大学附属长征医院病原真菌分子生物学研究所, 上海200003

摘要: 随着免疫受损人群的增多,近年来侵袭性真菌感染的发生率逐渐升高,由此导致的致病率也逐年上升。如何及时诊断并有效的治疗侵袭性真菌感染已成为临床上面临的挑战之一。该文就侵袭性真菌感染的流行病学、病因学及现有的治疗策略等方面进行综述。

关键词: 侵袭性真菌感染 流行病学 抗真菌药 治疗

The situation in the treatment of invasive fungal infections

LI Meng, LIAO Wan-qing

Shanghai Key Laboratory of Molecular Mycology & PLA Key Laboratory of Fungal Diseases, ChangZheng Hospital, Second Military Medical University, Shanghai 200003, China

Abstract: The incidence of invasive fungal infections(IFIs) had increased over the last decade with the rise of risk population of patients who suffered from immunologic deficit.The morbidity and mortality of IFIs are high and the management of these conditions is a great challenge.This article reviews the epidemiology of the IFIs,the recently developed antifungal agents and the newly therapeutic strategies.

Keywords: invasive fungal infections epidemiology antifungal agents treatment

收稿日期 2011-09-18 修回日期 网络版发布日期

DOI:

基金项目:

通讯作者: 廖万清,E-mail: liaowanqing@sohu.Com

作者简介: 李梦,女(汉族),博士研究生在读.E-mail: lemonlives@gmail.com

作者Email: liaowanqing@sohu.Com

参考文献:

[1] Bennet JE.Echinocandins for candidemia in adults without neu-tropenia[J].N Engl J Med,2006,355(11): 1154-1159.

[2] Pfaller MA,Pappas PG,Wingard JR.Invasive fungal patho-gens:current epidemiological trends[J].Clin Infect Dis,2006,43(Suppl 1): S3-14.

[3] Pfaller MA,Diekema DJ.Rare and emerging opportunistic fun-gal pathogens:concern for resistance beyond Candida albicansand Aspergillus fumigatus[J].J Clin Microbiol,2004,42(10): 4419-4431.

[4] Segal BH,Almyroudis NG,Battiwalla M,et al.Prevention and early treatment of invasive fungal infection in patients with canc-er and neutropenia and in stem cell transplant recipients in theera of newer broad-spectrum antifungal agents and diagnostic ad-juncts[J].Clin Infect Dis,2007,44(3): 402-409.

[5] Cornely OA,Maertens J,Bresnik M,et al.AmBiLoad Trial StudyGroup.Liposomal amphotericin B as initial therapy for invasivemold infection:a randomized trial comparing a high-loading doseregimen with standard dosing(AmBiLoad Trial)[J].Clin InfectDis,2007,44(10): 1289-1297.

[6] Johnson LB,Kauffman CA.Voriconazole: a new triazole antifun-gal agent[J].Clin Infect Dis,2003,36

扩展功能

本文信息

- ▶ Supporting info
- ▶ PDF(KB)
- ▶ [HTML全文]
- ▶ 参考文献[PDF]
- ▶ 参考文献

服务与反馈

- ▶ 把本文推荐给朋友
- ▶ 加入我的书架
- ▶ 加入引用管理器
- ▶ 引用本文
- ▶ Email Alert
- ▶ 文章反馈
- ▶ 浏览反馈信息

本文关键词相关文章

- ▶ 侵袭性真菌感染
- ▶ 流行病学
- ▶ 抗真菌药
- ▶ 治疗

本文作者相关文章

- ▶ 李梦
- ▶ 廖万清

PubMed

- ▶ Article by LI Meng
- ▶ Article by LIAO Wan-qing

(5): 630-637.

[7] Dannaoui E, Meletiadis J, Mouton JW, et al. In vitro susceptibilities of zygomycetes to conventional and new antifungals[J]. *J Antimicrob Chemother*, 2003, 51(1): 45-52.

[8] Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis[J]. *N Engl J Med*, 2002, 347(8): 408-415.

[9] Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less common, emerging, or refractory fungal infections[J]. *Clin Infect Dis*, 2003, 36(9): 1122-1131.

[10] Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease[J]. *N Engl J Med*, 2007, 356(4): 335-347.

[11] Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia[J]. *N Engl J Med*, 2007, 356(4): 348-359.

[12] Keating GM, Figgitt DP. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis[J]. *Drugs*, 2003, 63(20): 2235-2263.

[13] Groll AH, Kolve H. Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy[J]. *Eur J Clin Microbiol Infect Dis*, 2004, 23(4): 256-270.

[14] Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, et al. In vitro antifungal susceptibilities of *Trichosporon* species[J]. *Antimicrob Agents Chemother*, 2002, 46(4): 1144-1146.

[15] Petrovic J, Ngai A, Bradshaw S, et al. Efficacy and safety of caspofungin in solid organ transplant recipients[J]. *Transplant Proc*, 2007, 39(10): 3117-3120.

[16] Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis[J]. *N Engl J Med*, 2002, 347(25): 2020-2029.

[17] Maertens J, Raad I, Pettrikos G, et al. Efficacy and safety of caspofungin for the treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy[J]. *Clin Infect Dis*, 2004, 39(11): 1563-1571.

[18] Wingard JR. Empirical antifungal therapy in treating febrile neutropenic patients[J]. *Clin Infect Dis*, 2004, 39(Suppl 1): S38-43.

[19] Wheat LJ. Antigen detection, serology, and molecular diagnosis of invasive mycoses in the immunocompromised host[J]. *Transpl Infect Dis*, 2006, 8(3): 128-139.

[20] Glasmacher A, Prentice A, Gorschluter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients[J]. *J Clin Oncol*, 2003, 21(24): 4615-4626.

[21] 周新. 侵袭性真菌感染的新动向和治疗新策略[J]. *实用临床医药杂志*, 2010, 7(14): 1-2.

[22] Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia[J]. *J Clin Oncol*, 2001, 19(1): 253-259.

[23] Becker MJ, Lugtenburg EJ, Cornelissen JJ, et al. Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis[J]. *Br J Haematol*, 2003, 121(3): 448-457.

[24] Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial[J]. *Clin Infect Dis*, 2007, 44(1): 2-12.

[25] Hennen CR. Pharmacoeconomic evaluations of antifungal therapies[J]. *Curr Med Res Opin*, 2009, 25(7): 1751-1758.

[26] Arenas-Guzman R, Tosti A, Hay R, et al. Pharmacoeconomics—an aid to better decision-making[J]. *J Eur Acad Dermatol Venereol*, 2005, 19 Suppl 1: 34-39.

[27] Johnson MD, Kleinberg M, Danziger L, et al. Pharmacoeconomics of antifungal pharmacotherapy—challenges and future directions[J]. *Expert Opin Pharmacother*, 2005, 6(15): 2617-2632.

[28] Rubio-Terres C, Grau S. Pharmacoeconomics of voriconazole[J]. *Expert Opin Pharmacother*, 2010, 11(6): 877-887.

[29] Herbrecht R, Rajagopalan S, Danna R, et al. Comparative survival and cost of antifungal therapy: posaconazole versus standard antifungals in the treatment of refractory invasive aspergillosis[J]. *Curr Med Res Opin*, 2010, 26(10): 2457-2464.

[30] Spellberg BJ, Filler SG, Edwards JE. Current treatment strategies for disseminated candidiasis[J]. *Clin Infect Dis*, 2006, 42(2): 244-251.

[31] Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study[J]. *Clin Infect Dis*, 2006, 43(1): 25-31.

本刊中的类似文章

1. 江爱萍, 黄剑清, 卢万丁, 徐明, 吴建华. PCR指纹图谱分析在念珠菌性阴道炎、龟头炎流行病学研究中的应用[J]. *中国真菌学杂志*, 2012, (2): 82-84, 115

2. 杨利红, 赵颖, 严淑贤, 邴斐, 章强强, 徐金华. 上海新泾社区50岁以上居民足癣患病情况调查[J]. *中国真菌学杂志*, 2012, (2): 92-94

3. 中国中西医结合学会皮肤性病专业委员会, 中华医学会皮肤性病学分会真菌学组. 手癣和足癣的诊疗指南[J]. *中国真菌学杂志*, 2012, (2): 109-110

4. 郑岳臣. 脓癣诊治难点分析[J]. *中国真菌学杂志*, 2012, 7(1): 1-3

